“…Arginine vasopressin is known to contribute to water reabsorption and amniotic fluid volume in the fetal kidney via action on type-2 receptors on the collecting tubules (see Robillard, Porter & Jose, 1994), promoting the reabsorption of water and thereby reducing UO. Arginine vasopressin infusion into the fetus increases urine osmolarity and decreases urine flow rate (Lingwood, Hardy, Horacek, McPhee, Scoggins & Wintour, 1978), and fetal dehydration is associated with raised fetal AVP and decreased UO (Herin, Kim, Schrier, Meschia & Battaglia, 1988). Furthermore, while oliguria resulting from prostaglandin blockade is associated with a rise in circulating AVP (Walker, Moore, Cheung & Brace, 1992), similar treatment is not associated with altered RBF (Arnold-Aldea, Auslender & Parer, 1991) …”